BeiGene Ltd. (BGNE) Scheduled to Post Quarterly Earnings on Friday
BeiGene Ltd. (NASDAQ:BGNE) will be announcing its earnings results on Friday, October 7th. Investors that are interested in registering for the company’s conference call can do so using this link.
BeiGene (NASDAQ:BGNE) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($0.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.68) by $0.05. The business earned $0.40 million during the quarter, compared to analysts’ expectations of $2.08 million. BeiGene’s revenue for the quarter was down 71.4% compared to the same quarter last year. On average, analysts expect BeiGene to post $-3.38 EPS for the current fiscal year and $-3.38 EPS for the next fiscal year.
Shares of BeiGene Ltd. (NASDAQ:BGNE) opened at 31.68 on Thursday. The firm’s 50-day moving average price is $30.17 and its 200-day moving average price is $29.19. The firm’s market capitalization is $1.04 billion. BeiGene Ltd. has a 12 month low of $22.51 and a 12 month high of $35.60.
A number of equities analysts have commented on the company. Zacks Investment Research raised BeiGene from a “sell” rating to a “hold” rating in a research note on Monday, September 12th. Maxim Group assumed coverage on BeiGene in a research note on Wednesday, September 21st. They issued a “buy” rating and a $41.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $40.00.
In other news, Director Donald W. Glazer sold 67,252 shares of the business’s stock in a transaction on Wednesday, September 21st. The stock was sold at an average price of $31.42, for a total transaction of $2,113,057.84. Following the completion of the sale, the director now owns 4,882,000 shares in the company, valued at $153,392,440. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Donald W. Glazer sold 41,463 shares of the business’s stock in a transaction on Wednesday, September 28th. The stock was sold at an average price of $30.66, for a total value of $1,271,255.58. Following the sale, the director now owns 4,881,997 shares of the company’s stock, valued at approximately $149,682,028.02. The disclosure for this sale can be found here.
Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in BeiGene by 3,410.1% in the second quarter. BlackRock Inc. now owns 3,826 shares of the company’s stock worth $114,000 after buying an additional 3,717 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in BeiGene by 67.9% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 6,404 shares of the company’s stock worth $191,000 after buying an additional 2,589 shares in the last quarter. Vident Investment Advisory LLC bought a new stake in BeiGene during the second quarter worth approximately $678,000. Finally, FMR LLC increased its stake in BeiGene by 34.0% in the second quarter. FMR LLC now owns 2,300,337 shares of the company’s stock worth $68,550,000 after buying an additional 583,277 shares in the last quarter. Institutional investors own 26.26% of the company’s stock.
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.
Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.